This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /sign-in page

You can view 5 more pages before signing in

Dengue-like fever

Authoring team

  • Chikungunya fever is a viral infection caused by an alphavirus (family Togaviridae) found in humans and non-human primates.
  • The virus is transmitted primarily by daylight-biting Aedes mosquitoes (e.g. Aedes aegypti and Aedes albopictus).
  • The name "chikungunya" derives from Swahili, meaning "stooped over", "that which bends up" or "walking bent over", reflecting the prominent symptom of severe joint pain (arthralgia).

Epidemiology and transmission

  • Natural cycles include human–mosquito–human transmission and an African forest epizootic cycle involving monkeys.
  • Aedes aegypti (domestic vector) is closely associated with human habitation, feeding almost exclusively on humans throughout the tropics.
  • Aedes albopictus (Asian tiger mosquito) feeds on mammals and birds, can thrive away from human habitation and was implicated in the major Réunion outbreak (265,000 cases; 34% of the population) (1).
  • Circulates in tropical and subtropical regions of Asia, Africa, Latin America and the Caribbean; established vectors in parts of southern Europe present a risk for localised European transmission.

Clinical features

  • Incubation period is typically 2 to 7 days.
  • Acute onset features include high fever, severe joint pain (arthralgia), muscle pain (myalgia), headache, nausea, vomiting, photophobia and a maculopapular rash.
  • Joint pain is often debilitating, typically affecting small peripheral joints (wrists, ankles); while usually self-limiting over 1 to 2 weeks, chronic arthralgia can persist for months or years in a significant proportion of patients (4).
  • High-risk groups for severe disease include adults aged over 65 years, neonates and immunocompromised individuals.
  • Presentation varies by age: infants often show abrupt fever, facial flushing and generalised rash 3 to 5 days later; older children present with fever, headache, myalgia and arthralgia; adults predominantly present with severe arthralgia or arthritis.

Diagnosis and treatment

  • Diagnostic confirmation: IgM-capture ELISA or reverse-transcriptase PCR (RT-PCR) on acute-phase samples.
  • Management is predominantly supportive (analgesia, hydration and rest); DMARDs (methotrexate, sulfasalazine, leflunomide and hydroxychloroquine) have been used for persistent post-viral arthralgia but show limited efficacy (5).
  • Standard mosquito bite avoidance measures remain essential for prevention.

Vaccination policy and UK guidance

  • Vimkunya (VLP vaccine): a non-replicating virus-like particle (VLP) vaccine licensed in the UK for individuals aged 12 years and over (8).
  • Joint Committee on Vaccination and Immunisation (JCVI) advice: may be considered for individuals aged 12 years and over travelling to areas with active outbreaks, long-term or frequent travellers to transmission areas in the past 5 years, or laboratory staff working with the virus (9).
  • Immunogenicity: elicits seroresponse rates of 98% (ages 12 to 64 years) and 87% (ages 65 years and over) at 22 days post-vaccination, falling to 86% and 76% respectively at 6 months (9).
  • Platform safety: because safety concerns regarding Ixchiq were specific to its live-attenuated platform, the JCVI does not advise additional restrictions on Vimkunya (9).
  • Ixchiq (live-attenuated vaccine): live-attenuated chikungunya vaccine (6); following a safety review by the Commission on Human Medicines (CHM) regarding serious adverse events in older adults, the MHRA withdrew its UK marketing authorisation (7,9).
  • UK guidance: healthcare professionals must not prescribe, supply or administer Ixchiq, and must update materials to remove references to it; travellers previously vaccinated with Ixchiq do not require specific action unless experiencing suspected adverse reactions (7).

References:

  1. Anon. Epidémie de chikungunya à La Réunion. Cire La Réunion-Mayotte. 2006.
  2. Ligon BL. Chikungunya: an overview. Semin Pediatr Infect Dis. 2006;17(2):99-104.
  3. Mourya DT, Mishra AC. Chikungunya fever. Lancet. 2006;368(9531):186-187.
  4. Brighton SW et al. Chikungunya virus infection: a retrospective study of 107 cases. S Afr Med J. 1983;63:313-315.
  5. de Lima Cavalcanti TYV et al. A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development. Viruses. 2022;14(5):969.
  6. Ng LFP, Rénia L. Live-attenuated chikungunya virus vaccine. Cell. 2024;187(4):813.
  7. Medicines and Healthcare products Regulatory Agency (MHRA). IXCHIQ chikungunya vaccine: UK marketing authorisation withdrawn following safety review. Drug Safety Update. 2026;20(3):2.
  8. Medicines and Healthcare products Regulatory Agency (MHRA). Public Assessment Report: Vimkunya chikungunya vaccine. MHRA. 2025.
  9. Joint Committee on Vaccination and Immunisation (JCVI). Chikungunya vaccine in UK travellers: JCVI advice. GOV.UK. Updated 6 November 2026.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.